147 related articles for article (PubMed ID: 33762097)
1. Have any strategies in Ph-like ALL been shown to be effective?
Aldoss I; Advani AS
Best Pract Res Clin Haematol; 2021 Mar; 34(1):101242. PubMed ID: 33762097
[TBL] [Abstract][Full Text] [Related]
2. Adults with Philadelphia Chromosome-Like Acute Lymphoblastic Leukemia: Considerations for Allogeneic Hematopoietic Cell Transplantation in First Complete Remission.
Aldoss I; Kamal MO; Forman SJ; Pullarkat V
Biol Blood Marrow Transplant; 2019 Feb; 25(2):e41-e45. PubMed ID: 30292743
[TBL] [Abstract][Full Text] [Related]
3. Hematopoietic Cell Transplantation for Philadelphia Chromosome Negative Adult Acute Lymphoblastic Leukemia in the Modern Era of Immune Therapy.
Yurkiewicz I; Craig J; Muffly L
Curr Hematol Malig Rep; 2020 Jun; 15(3):187-193. PubMed ID: 32358681
[TBL] [Abstract][Full Text] [Related]
4. Blinatumomab administered concurrently with oral tyrosine kinase inhibitor therapy is a well-tolerated consolidation strategy and eradicates measurable residual disease in adults with Philadelphia chromosome positive acute lymphoblastic leukemia.
King AC; Pappacena JJ; Tallman MS; Park JH; Geyer MB
Leuk Res; 2019 Apr; 79():27-33. PubMed ID: 30831480
[TBL] [Abstract][Full Text] [Related]
5. Ph-like acute lymphoblastic leukemia in adults: understanding pathogenesis, improving outcomes, and future directions for therapy.
Aldoss I; Gu Z; Afkhami M; Mokhtari S; Pullarkat V
Leuk Lymphoma; 2023 Jun; 64(6):1092-1101. PubMed ID: 37021793
[TBL] [Abstract][Full Text] [Related]
6. Feasible outcome of blinatumomab followed by allogeneic hematopoietic cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first salvage.
Yoon JH; Min GJ; Park SS; Park S; Lee SE; Cho BS; Eom KS; Kim YJ; Kim HJ; Min CK; Cho SG; Kim DW; Lee JW; Lee S
Cancer Med; 2019 Dec; 8(18):7650-7659. PubMed ID: 31691536
[TBL] [Abstract][Full Text] [Related]
7. New approaches to the treatment of older adults with acute lymphoblastic leukemia.
Schwartz M; Wieduwilt MJ
Semin Hematol; 2020 Jul; 57(3):122-129. PubMed ID: 33256901
[TBL] [Abstract][Full Text] [Related]
8. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies.
Aldoss I; Yang D; Malki MMA; Mei M; Mokhtari S; Artz A; Cao T; Salhotra A; Ali H; Aribi A; Khaled S; Arslan S; Sandhu K; Koller P; Mansour J; Spielberger R; Stein A; Snyder D; Marcucci G; Forman SJ; Nakamura R; Pullarkat V
Transplant Cell Ther; 2021 Mar; 27(3):255.e1-255.e9. PubMed ID: 33781525
[TBL] [Abstract][Full Text] [Related]
9. Minimal residual disease (MRD) positivity at allogeneic hematopoietic cell transplantation, not the quantity of MRD, is a risk factor for relapse of Philadelphia chromosome-positive acute lymphoblastic leukemia.
Akahoshi Y; Arai Y; Nishiwaki S; Mizuta S; Marumo A; Uchida N; Kanda Y; Sakai H; Takada S; Fukuda T; Fujisawa S; Ashida T; Tanaka J; Atsuta Y; Kako S
Int J Hematol; 2021 Jun; 113(6):832-839. PubMed ID: 33570732
[TBL] [Abstract][Full Text] [Related]
10. How should we treat older adults with Ph+ adult ALL and what novel approaches are being investigated?
Wieduwilt MJ
Best Pract Res Clin Haematol; 2017 Sep; 30(3):201-211. PubMed ID: 29050693
[TBL] [Abstract][Full Text] [Related]
11. Blinatumomab or Inotuzumab Ozogamicin as Bridge to Allogeneic Stem Cell Transplantation for Relapsed or Refractory B-lineage Acute Lymphoblastic Leukemia: A Retrospective Single-Center Analysis.
Stelmach P; Wethmar K; Groth C; Wenge DV; Albring J; Mikesch JH; Schliemann C; Reicherts C; Berdel WE; Lenz G; Stelljes M
Clin Lymphoma Myeloma Leuk; 2020 Oct; 20(10):e724-e733. PubMed ID: 32646833
[TBL] [Abstract][Full Text] [Related]
12. Hematopoietic Stem Cell Transplantation for Adult Philadelphia-Negative Acute Lymphoblastic Leukemia in the First Complete Remission in the Era of Minimal Residual Disease.
Bourlon C; Lacayo-Leñero D; Inclán-Alarcón SI; Demichelis-Gómez R
Curr Oncol Rep; 2018 Mar; 20(4):36. PubMed ID: 29577208
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic Hematopoietic Stem Cell Transplantation, Especially Haploidentical, May Improve Long-Term Survival for High-Risk Pediatric Patients with Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia in the Tyrosine Kinase Inhibitor Era.
Xue YJ; Cheng YF; Lu AD; Wang Y; Zuo YX; Yan CH; Wu J; Sun YQ; Suo P; Chen YH; Chen H; Jia YP; Liu KY; Han W; Xu LP; Zhang LP; Huang XJ
Biol Blood Marrow Transplant; 2019 Aug; 25(8):1611-1620. PubMed ID: 30537550
[TBL] [Abstract][Full Text] [Related]
14. Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: Results from Japanese Pediatric Leukemia/Lymphoma Study Group (JPLSG) Study Ph(+) ALL04.
Manabe A; Kawasaki H; Shimada H; Kato I; Kodama Y; Sato A; Matsumoto K; Kato K; Yabe H; Kudo K; Kato M; Saito T; Saito AM; Tsurusawa M; Horibe K
Cancer Med; 2015 May; 4(5):682-9. PubMed ID: 25641907
[TBL] [Abstract][Full Text] [Related]
15. Diagnostic and therapeutic advances in adults with acute lymphoblastic leukemia in the era of gene analysis and targeted immunotherapy.
Yoon JH; Lee S
Korean J Intern Med; 2024 Jan; 39(1):34-56. PubMed ID: 38225824
[TBL] [Abstract][Full Text] [Related]
16. Dasatinib-induced complete molecular response after allogeneic hematopoietic stem cell transplantation in Philadelphia chromosome-positive acute lymphoblastic leukemia resistant to prior imatinib-containing regimen: a case report and discussion.
Czyz A; Lewandowski K; Kroll R; Komarnicki M
Med Oncol; 2010 Dec; 27(4):1123-6. PubMed ID: 19885746
[TBL] [Abstract][Full Text] [Related]
17. Salvage therapy for children with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia.
Kodama Y; Manabe A; Kawasaki H; Kato I; Kato K; Sato A; Matsumoto K; Kato M; Hiramatsu H; Sano H; Kaneko T; Oda M; Saito AM; Adachi S; Horibe K; Mizutani S; Ishii E; Shimada H
Pediatr Blood Cancer; 2017 Aug; 64(8):. PubMed ID: 28084041
[TBL] [Abstract][Full Text] [Related]
18. Sequencing of novel agents in relapsed/refractory B-cell acute lymphoblastic leukemia: Blinatumomab and inotuzumab ozogamicin may have comparable efficacy as first or second novel agent therapy in relapsed/refractory acute lymphoblastic leukemia.
Badar T; Szabo A; Dinner S; Liedtke M; Burkart M; Shallis RM; Yurkiewicz IR; Kuo E; Khan MA; Balasubramanian S; Yang J; Hefazi M; Podoltsev N; Patel A; Curran E; Wang A; Arslan S; Aldoss I; Siebenaller C; Mattison RJ; Litzow MR; Wadleigh M; Advani AS; Atallah E
Cancer; 2021 Apr; 127(7):1039-1048. PubMed ID: 33259056
[TBL] [Abstract][Full Text] [Related]
19. Effect of Blinatumomab vs Chemotherapy on Event-Free Survival Among Children With High-risk First-Relapse B-Cell Acute Lymphoblastic Leukemia: A Randomized Clinical Trial.
Locatelli F; Zugmaier G; Rizzari C; Morris JD; Gruhn B; Klingebiel T; Parasole R; Linderkamp C; Flotho C; Petit A; Micalizzi C; Mergen N; Mohammad A; Kormany WN; Eckert C; Möricke A; Sartor M; Hrusak O; Peters C; Saha V; Vinti L; von Stackelberg A
JAMA; 2021 Mar; 325(9):843-854. PubMed ID: 33651091
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of inotuzumab ozogamicin in patients with Philadelphia chromosome-positive relapsed/refractory acute lymphoblastic leukemia.
Stock W; Martinelli G; Stelljes M; DeAngelo DJ; Gökbuget N; Advani AS; O'Brien S; Liedtke M; Merchant AA; Cassaday RD; Wang T; Zhang H; Vandendries E; Jabbour E; Marks DI; Kantarjian HM
Cancer; 2021 Mar; 127(6):905-913. PubMed ID: 33231879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
